卡普瑞林 | 193273-66-4

• 物质功能分类: 生物化工 - 抑制剂
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 卡普瑞林
• 中文别名: (S)-O-苯甲基乳醛-N-(叔-丁氧基羰基)腙
• 英文名称: capromorelin
• 英文别名: CP 424-391；2-amino-N-[(1R)-2-[(3aR)-2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl-propanamide；2-amino-N-[(1R)-1-[[(3aR)-3a-benzyl-2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-2-(benzyloxy)ethyl]-2-methylpropionamide；2-amino-N-[1-(3a-(3aR)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]pyridin-5-yl)-1-(2R)-benzyloxymethyl-2-oxoethyl]isobutyramide；CP 424391；CP-424391；N-[(2R)-1-[(3aR)-3a-benzyl-2-methyl-3-oxo-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-1-oxo-3-phenylmethoxypropan-2-yl]-2-amino-2-methylpropanamide
• CAS: 193273-66-4
• 化学式: C₂₈H₃₅N₅O₄
• 分子量: 505.617
• InChiKey: KVLLHLWBPNCVNR-SKCUWOTOSA-N

物化性质

• 密度：
  1.25

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 储存条件：
  -20°C

制备方法与用途

卡普瑞林是一种生长素释放肽激动剂，可用于治疗哺乳动物的胰岛素抗性。

Capromorelin Tartrate（CP 424391-18）是一种growth hormone sECretagogue (GHS) 类药物，作为 ghrelin rECeptor 的激动剂，可用作狗的一种刺激食欲的新疗法。其对 hGHS-R1a 的 Ki 值为 7 nM，对大鼠垂体细胞的 EC50 值为 3 nM。

靶点	值
rat pituicyte (Cell-free assay)	3 nM (EC50)
hGHS-R1a (Cell-free assay)	7 nM (Ki)

反应信息

• 作为反应物：
  描述：

  L-酒石酸 、 卡普瑞林 在 异丙醇 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 生成 酒石酸卡莫瑞林
  参考文献：
  名称：

  WO2014/192294

  摘要：

  公开号：
• 作为产物：
  描述：

  1-叔丁基-3-苄基-4-氧代哌啶-1,3-二羧酸-3-甲酯 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 25.0h， 生成 卡普瑞林
  参考文献：
  名称：

  Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs)

  摘要：

  Novel pyrazolinone-piperidine dipeptide derivatives were synthesized and evaluated as growth hormone secretagogues (GHSs). Two analogues, capromorelin (5, CP-424391-18, hGHS-R1a K-i=7 nM, rat pituicyte EC50=3 nM) and the des-methyl analogue 5c (hGHS-R1a K-i=17 nM, rat pituicyte EC50 = 3 nM), increased plasma GH levels in an anesthesized rat model, with ED50 values less than 0.05 mg/kg iv. Capromorelin showed enhanced intestinal absorption in rodent models and exhibited superior pharmacokinetic properties, including high bioavailabilities in two animal species [F(rat) = 65%, F(dog) = 44%]. This short-duration GHS was orally active in canine models and was selected as a development candidate for the treatment of musculoskeletal frailty in elderly adults. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00433-9

文献信息

• Methods of treatment using an EP2 selective receptor agonist
  申请人：Constan A. Alexander

  公开号：US20050203086A1

  公开（公告）日：2005-09-15

  The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP 2 selective receptor agonist.

  本发明涉及使用EP2选择性受体激动剂治疗肺动脉高压、促进关节融合、促进肌腱和韧带修复、减少继发性骨折的发生、治疗缺血性坏死、促进软骨修复、促进肢体移植后的骨愈合、促进肝脏再生、促进伤口愈合、减少胃溃疡的发生、治疗高血压、促进牙齿珐琅质或手指甲和脚趾甲的生长、治疗青光眼、治疗眼高压以及修复由转移性骨疾病引起的损伤的方法。
• [EN] AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR<br/>[FR] LIGANDS D'AMIDES ET DE SULFONAMIDES DU RECEPTEUR OESTROGENIQUE
  申请人：PFIZER PROD INC

  公开号：WO2004026823A1

  公开（公告）日：2004-04-01

  The present invention provides estrogen receptor (ER) ligands of structural formula (I) the pharmaceutically acceptable salts, stereoisomers, and prodrugs thereof, and the pharmaceutically acceptable salts of the prodrugs, wherein R1, R2, R3, R4, R5, X, and Q are as defined herein. The invention further provides pharmaceutical compositions comprising the compounds of formula (I), and methods for treating or preventing diseases, disorders, conditions, or symptoms mediated by an ER which comprise administering to a mammalian subject in need of treatment therewith, an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug. The invention further provides pharmaceutical compositions comprising combinations of the compounds of formula (I) and one or more of sodium fluoride, estrogen, a bone anabolic agent, a growth hormone or growth hormone secretagogue, a prostaglandin agonist/antagonist, and a parathyroid hormone, and methods of treating or preventing diseases, disorders, conditions, or symptoms mediated by an ER comprising the administration of an effective amount of such combination to a mammalian subject in need of treatment therewith.

  本发明提供了结构式（I）的雌激素受体（ER）配体及其药用盐、立体异构体和前药，以及前药的药用盐，其中R1、R2、R3、R4、R5、X和Q如本文所定义。该发明还提供了包括式（I）化合物的药物组合物，以及用于治疗或预防由ER介导的疾病、紊乱、症状或症状的方法，包括向需要治疗的哺乳动物主体施用式（I）化合物的有效量，或其药用盐、立体异构体或前药，或前药的药用盐，或包括式（I）化合物的药物组合物，或其药用盐、立体异构体或前药，或前药的药用盐。该发明还提供了包括式（I）化合物和一种或多种氟化钠、雌激素、骨骼阳性代理、生长激素或生长激素分泌素、前列腺素激动剂/拮抗剂和甲状旁腺激素的药物组合物的药物组合物，以及治疗或预防由ER介导的疾病、紊乱、症状或症状的方法，包括向需要治疗的哺乳动物主体施用这种组合物的有效量。
• Benzimidazole compounds and their use as estrogen agonists/antagonists
  申请人：——

  公开号：US20040002524A1

  公开（公告）日：2004-01-01

  This invention relates to compounds, in particular benzimidazoles, that are useful as estrogen agonists and/or antagonists and pharmaceutical uses thereof. The present invention also relates to benzimidazoles that are selective for the ER&bgr; receptor and pharmaceutical uses thereof.

  本发明涉及一种化合物，特别是苯并咪唑，其作为雌激素激动剂和/或拮抗剂具有用途，并且具有药用用途。本发明还涉及对ER&bgr;受体具有选择性的苯并咪唑及其药用用途。
• [EN] FUSED HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSES HETEROCYCLIQUES FUSIONNES
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2005046698A1

  公开（公告）日：2005-05-26

  This invention provides fused heterocyclic compounds, pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12 related disease and disorders.

  这项发明提供了融合杂环化合物，这些化合物的药物组合物，以及使用这些化合物用于治疗IL-12相关疾病和紊乱的方法。
• Methods of treatment and kits comprising a growth hormone secretagogue
  申请人：——

  公开号：US20030105114A1

  公开（公告）日：2003-06-05

  The present invention relates to methods of treating bulimia nervosa, male erectile dysfunction, female sexual dysfunction, thyroid cancer, breast cancer, or ameliorating ischemic nerve or muscle damage. The present invention also relates to kits that can be used in the treatment of bulimia nervosa, male erectile dysfunction, female sexual dysfunction, thyroid cancer, breast cancer, or ameliorating ischemic nerve or muscle damage. The present invention further relates to increasing gastrointestinal motility after surgery and increasing gastrointestinal motility in patients who have been administered an agent that decreases gastrointestinal motility.

  本发明涉及治疗厌食症、男性勃起功能障碍、女性性功能障碍、甲状腺癌、乳腺癌或改善缺血性神经或肌肉损伤的方法。本发明还涉及可用于治疗厌食症、男性勃起功能障碍、女性性功能障碍、甲状腺癌、乳腺癌或改善缺血性神经或肌肉损伤的试剂盒。本发明还涉及术后增加胃肠道蠕动和在接受降低胃肠道蠕动试剂的患者中增加胃肠道蠕动。